1 The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute; Fred & Pamela Buffett Cancer Center; Mayo Clinic Cancer Center; UCSF Helen Diller Family Comprehensive Cancer Center; Vanderbilt-Ingram Cancer Center; The University of Texas MD Anderson Cancer Center; Dana-Farber/Brigham and Women's Cancer Center; Robert H. Lurie Comprehensive Cancer Center of Northwestern University; Massachusetts General Hospital Cancer Center; Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute; Fox Chase Cancer Center; UC San Diego Moores Cancer Center; University of Michigan Rogel Cancer Center; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; University of Alabama at Birmingham Comprehensive Cancer Center; City of Hope Comprehensive Cancer Center; Yale Cancer Center/Smilow Cancer Hospital; Stanford Cancer Institute; Roswell Park Comprehensive Cancer Center; University of Colorado Cancer Center; University of Washington/Seattle Cancer Care Alliance; Memorial Sloan Kettering Cancer Center; Duke Cancer Institute; Moffitt Cancer Center; Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine; University of Wisconsin Carbone Cancer Center; Huntsman Cancer Institute at the University of Utah; and National Comprehensive Cancer Network.
The NCCN Guidelines for Neuroendocrine and Adrenal Tumors provide recommendations for the management of adult patients with neuroendocrine tumors (NETs), adrenal gland tumors, pheochromocytomas, and paragangliomas. Management of NETs relies heavily on the site of the primary NET. These NCCN Guidelines Insights summarize the management options and the 2018 updates to the guidelines for locoregional advanced disease, and/or distant metastasis originating from gastrointestinal tract, bronchopulmonary, and thymus primary NETs.
Provided content development and/or authorship assistance.